Reconnect Labs

About Reconnect Labs

Reconnect Labs AG is a clinical-stage biopharmaceutical company based in Winterthur, Switzerland, established in 2021. As a spin-off from the University of Zurich, the company was founded by a team of neuroscientists: Davor Kosanic (CEO), Milan Scheidegger (CMO), Dario-Alessandro Dornbierer (CSO), Michael Kometer (Chairman), Robin von Rotz (CCO), and Daniel Claussen (CBO). The founding team leverages extensive experience in neuroscience, psychiatry, psychopharmacology, and clinical research to address shortcomings of existing treatments for mental health conditions.

The company's business model is centered on the research and development of a portfolio of proprietary drug candidates, aiming to secure regulatory approval and commercialize these treatments. The primary clients are patients suffering from specific mental health and neurological disorders. Reconnect Labs operates in the biopharmaceutical market, specifically focusing on precision psychiatry for conditions like insomnia, anxiety, and substance use disorders. Revenue generation will likely be realized through licensing agreements, partnerships with larger pharmaceutical companies, and direct sales of approved therapeutics. The company has received funding from the Lichtsteiner Foundation.

Reconnect Labs is developing a pipeline of what it terms "Regenerative Therapeutics™" designed to offer both immediate symptom relief and long-term, disease-modifying benefits. Its clinical pipeline includes three main candidates. RE03 is a repurposed, non-addictive α2 nor-adrenergic receptor agonist for treating insomnia in PTSD and stress-induced primary insomnia, which has shown to improve sleep architecture without common side effects like hangovers. RE02 is a patented, non-psychedelic 5-HT1A agonist formulated as a rapid-acting anxiolytic for treatment-resistant generalized anxiety disorder. RE01 is a patented, fixed-combination psychoplastogen (5-HT2A agonist and dopamine modulator) with a rapid onset and short duration, being investigated for cocaine and stimulant use disorder. The company's approach combines precision-formulated drugs with digital psychiatry tools for diagnostics, aiming for scalable and accessible treatments.